Interleukin Genetics Expands DNA Analysis Lab Operations to Meet Demand for Risk Assessment Tests
06/28/2006
Interleukin Genetics Expands DNA Analysis Laboratory Operations to Meet Demand for Risk Assessment Tests
Waltham, MA - June 28, 2006 – Interleukin Genetics (AMEX: ILI) today announced the completion of the expansion and upgrade of its Laboratory Operations. This will allow the company to meet the demand for its DNA risk assessment tests. Interleukin has added equipment and staff to enable the company to improve turnaround time for test results and to increase efficiencies and overall capacity for future growth.
“Interleukin Genetics has added the throughput capacity to meet the demand for our new DNA based cardiovascular and nutritional wellness risk assessment tests.” commented Ken Kornman, DDS, PhD, CEO of Interleukin Genetics.
“We are pleased that the early sales of our current DNA risk assessment tests exceeded expectations. These laboratory enhancements significantly improve test turnaround time to meet the needs of our customers,” continued Dr. Kornman.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing and commercializing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment, and its current development programs focus on osteoporosis, and weight management. Interleukin expects that these programs will also lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies and our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700
  |